As Chief Operating Officer at Kymanox from 2018, I had the privilege of steering a dynamic professional services firm through a period of extraordinary growth, transforming it from a nimble team of 30 with $7 million in revenue to a powerhouse of roughly 300 professionals generating north of $70 million. My journey at Kymanox is a testament to strategic foresight, adaptive leadership, and a relentless focus on balancing growth with quality, a challenge I met head-on in the fast-paced life sciences industry.
When I joined Kymanox, we were a small but mighty player, known for delivering high-quality solutions in biotechnology, pharmaceuticals, and medical devices. By 2019, we identified two hyper-growth areas that would define our trajectory: helping clients secure regulatory approval and commercialize combination products (therapeutics paired with delivery systems like auto-injectors, nasal sprays, and pre-filled syringes) and FDA remediation (addressing 483s, Warning Letters, and Consent Decrees). These opportunities were exciting but came with a critical challenge: scaling our organization to meet surging demand without compromising quality or profitability.
In a professional services firm, scaling is a delicate balance. Grow too slowly, and you miss opportunities, risk turning down work, or deliver subpar results, damaging your reputation. Grow too fast, and expenses outpace revenue, eroding profitability, especially when underutilized capacity is the single biggest cost. As COO, my mission was to align supply with demand, building infrastructure and client-facing capacity to capitalize on these growth areas while maintaining Kymanox's reputation for excellence.
For the combination products segment, which could be delivered remotely, I developed a strategy to create a flexible, scalable talent pipeline. I built a network of pre-vetted, highly experienced engineers, scientists, and quality professionals, negotiating compensation packages in advance to enable rapid onboarding as projects were secured. This approach allowed us to quickly assemble tailored teams, ensuring we met client needs for regulatory submissions and commercialization without overstaffing. The result? We supported clients in launching innovative delivery systems, like on-body injectors, while maintaining project timelines and quality standards.
FDA remediation, however, required a different approach. These projects often demanded on-site presence for implementing mitigations and corrective actions, particularly for high-stakes Consent Decree responses. Building a network for every geographic location was impractical, so I forged strategic partnerships with recruiting and staffing firms with extensive databases. We complemented this by making key hires and, when necessary, relocating seasoned Kymanox staff to lead large-scale, on-site projects. This ensured that new resources integrated seamlessly, delivering the quality and branding Kymanox is known for, even under intense regulatory scrutiny.
These strategies paid off in spades. From 2018 to 2021, Kymanox grew from 60 to 180 people and revenue soared from $7 million to $33 million, with an EBITDA near 30%, a near-unheard-of margin for a professional services firm. Our success attracted private equity investment in 2021, fueling further expansion, both organic and inorganic, to approximately 300 employees and north of $70 million in revenue. This growth wasn't just about numbers; it was about building a sustainable, high-performing organization that empowered our team and delivered transformative solutions for our clients.